Pembro with chemotherapy or alone better then cetuximab combination, also improved responses to subsequent therapy.
Is ibrutininb’s days as a treatment for CLL over? Zanubrutinib is more effective and less toxic.
Combination immunotherapy beats chemotherapy, there is no data to compare against a chemo immunotherapy combination, but is an option for patients who may not tolerate chemotherapy.
Another option for combination chemo immunotherapy; we have a clinical trial in FCS now with another combination of chemotherapy + PD-L1 and TIGIT inhibitors, PLEASE CONSIDER IT FOR UNRESECTABLE NSCLC patients.
CAR-T for myeloma, impressive response rate, overall survival not reached.
Interesting enough, a patient asked me this question last week. IT IS DOABLE and seems to help in improving PFS. I hope one of our FCS radiation oncologists will share their thoughts, too.
Another radiation trial for older women. Radiation reduces local recurrence but not distant metastasis or overall survival. Again, hope one of our FCS radiation oncologists will share their thoughts in the comment section below.
This is not a trial, but really a very nice review article, too. A good read especially as we may start prescribing those meds locally.
For benign hematology, this is a good article about gene therapy in Hemophilia A.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
